Gsk PLC 6-K Filing

FAQ

Filing Documents

• a6205i.htm (6-K) — 2270KB
• 0001654954-25-013399.txt ( ) — 2271KB

From the Filing

IN OWN SHARES a6205i UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of November 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .       Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase: 21 November 2025 Aggregate number of ordinary shares of  31¼  pence each purchased: 180,000 Lowest price paid per share (GBp): 1,753.00p Highest price paid per share (GBp): 1,783.00p Volume-weighted average price paid per share (GBp): 1,766.33p   The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 30 September 2025. Since 30 September 2025, the Company has purchased 10,138,000 ordinary shares.   Following the above purchase, the Company will hold 235,602,844 ordinary shares in treasury and have 4,079,829,083 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,079,829,083. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 5.77 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.   Schedule of Purchases Shares purchased:    GSK plc (ISIN: GB00BN7SWP63) Date of purchases:     21 November 2025 Investment firm:      BNP Paribas SA   Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   16,875   1,782.50p   1,753.00p   1,765.84p   CHIX   60,702   1,782.50p   1,753.00p   1,765.59p   XLON   102,423   1,783.00p   1,753.00p   1,766.84p     Individual transactions:   Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   191   1756.5   CHIX   21-Nov-2025   08:00:54   20251121154630978   76   1756.5   XLON   21-Nov-2025   08:00:54   20251121154630980   211   1755.0   CHIX   21-Nov-2025   08:01:10   20251121154631284   249   1755.0   XLON   21-Nov-2025   08:01:10   20251121154631286   69   1755.0

View Full Filing

View this 6-K filing on SEC EDGAR